Celon Pharma S.A. concluded another agreement with the National Centre for Research and Development (NCRD)

On 26 August 2015, Celon Pharma S.A. signed another agreement with the National Centre for Research and Development for the co-financing of a project entitled: "New treatment for psychotic disorders and Huntington's disease with special focus on cognitive deficits" (NoteSzHD) as part of the STRATEGMED programme.

The funds obtained under the agreement will allow Celon Pharma S.A., the leader of the scientific and business consortium, to continue work on the project together with five other consortium members: The Nencki Institute of Experimental Biology PAS in the Polish Academy of Sciences, the Mossakowski Medical Research Centre in the Polish Academy of Sciences, Institute of Pharmacology of the Polish Academy of Sciences, the Medical University of Lodz and the Poznan University of Medical Sciences.
The total cost of the project is PLN 40,279,820 and the co-financing allocated to the Consortium amounts to 26,730,836.

The main objective of the STRATEGMED programme is to obtain fundamental progress in the fight against lifestyle diseases and regenerative medicine based on results of research and development works.

logo_sm_ostateczne_d

logo_ncbir

Tweet about this on TwitterShare on LinkedInShare on FacebookShare on Google+